Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health reports developments across a multinational biopharmaceutical and diagnostics business. Recurring updates cover operating results, financial guidance, BioReference laboratory testing services and digital access through BioReference Direct, and RAYALDEE commercialization through EirGen Pharma in Greater China.
The company also reports research collaborations and clinical development from ModeX Therapeutics, including its MSTAR multispecific antibody platform, MDX2301 for COVID-19 prevention, and MDX2003, a tetraspecific T-cell engager for B-cell lymphomas. News also includes pharmaceutical partnerships, diagnostic-service changes, investor presentations, and business updates tied to OPKO's pharmaceutical and diagnostics segments.
OPKO Health, Inc. (NASDAQ: OPK) reported strong financial results for the third quarter of 2020, achieving net income of $23.7 million ($0.04 per diluted share), significantly improving from a net loss of $62.0 million in Q3 2019. Revenues soared to $428.1 million, driven by a 61% increase in COVID-19 PCR testing, totaling approximately 3.5 million tests processed. The company also initiated a Phase 2 clinical trial for RAYALDEE to treat mild-to-moderate COVID-19. Notably, RAYALDEE prescriptions rose 13% year-over-year despite pandemic-related challenges.
BioReference Laboratories, part of OPKO Health (NASDAQ:OPK), has launched a multiplex test for COVID-19 and influenza A/B, now accepting specimens across the U.S. This innovative diagnostic tool is crucial for differentiating between these infections, especially as COVID-19 cases rise. The test allows healthcare providers to obtain results from a single sample, improving efficiency and conserving resources. Samples will be collected in supervised settings, not at BioReference Patient Service Centers. The initiative supports the identification of the correct infectious agent, aiding in effective patient management.
OPKO Health, Inc. (NASDAQ: OPK) will release its financial results for Q3 2020 on October 29, 2020, after U.S. market close. A conference call will follow at 4:30 p.m. Eastern Time, featuring management discussing operational updates and financial guidance. Interested participants can pre-register for the call or access it via a live audio webcast. For those unable to attend, a replay will be available. OPKO continues to focus on leveraging its expertise in the biopharmaceutical and diagnostics sectors.
BioReference Laboratories, an OPKO Health company (NASDAQ: OPK), has launched a COVID-19 testing program for New York City schools for the 2020-2021 academic year. This initiative is part of a collaboration with NYC's Department of Health, Health + Hospitals, and the Department of Education, involving specimen collection from over 950 schools. The program aims to enhance school safety during the pandemic. BioReference is known for its comprehensive testing services and operates a network of laboratory locations across the U.S.
OPKO Health, Inc. (NASDAQ: OPK) announced participation in two virtual investor conferences. The 13th Annual Barrington Research Fall Conference will take place on September 9, 2020, with management available for one-on-one calls. The H.C. Wainwright 22nd Annual Global Investment Virtual Conference is scheduled from September 14-16, 2020, featuring a company presentation on September 15 at 10:00 a.m. ET, along with one-on-one meetings. A live webcast will be accessible on OPKO’s investor website.
BioReference Laboratories, part of OPKO Health (NASDAQ:OPK), has launched a COVID-19 testing program for New York City school principals, teachers, and staff to ensure a safer return to school. The initiative, in collaboration with the NYC Department of Health and NYC Health + Hospitals, will collect specimens for PCR testing at eight locations, operating from 8:00 a.m. to 8:00 p.m. ET until September 7. This program highlights OPKO's commitment to supporting educational safety during the pandemic.
BioReference Laboratories, an OPKO Health company (NASDAQ:OPK), launched OnkoSight AdvancedTM, a next-generation sequencing (NGS) assay for detailed DNA mutational profiling of tumors. This assay aligns with National Comprehensive Cancer Network (NCCN) and World Health Organization (WHO) guidelines, aiding insights into common cancers. It features key biomarkers like Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) for advanced malignancies. The launch emphasizes patient-centric care through improved accuracy and faster turnaround, enhancing oncology management.
GeneDx, a subsidiary of OPKO Health, has partnered with Pediatrix Medical Group to provide advanced genomic sequencing in neonatal care. This collaboration will enhance diagnostic capabilities in NICUs, focusing on whole exome and whole genome sequencing under the Detect Genomix brand. With a network of over 2,200 affiliated physicians and more than 100 genetic counselors, the initiative aims to improve diagnostics for genetic disorders, a leading cause of neonatal morbidity and mortality. The services will be accessible across the U.S.
OPKO Health's subsidiary, GeneDx, has launched GenomeXpress, a rapid genome sequencing test that delivers results within seven days. This innovation enhances GeneDx's clinical genomics portfolio, offering three rapid sequencing options. GenomeXpress identifies pathogenic variants across both coding and non-coding regions of the genome, improving diagnostic accuracy for over 13,000 genetic diseases. The test promises to reduce hospital stays and healthcare costs while providing timely insights to clinicians and patients.
OPKO Health, Inc. (NASDAQ: OPK) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 10, 2020, at 9:00 a.m. Eastern time. Management will also engage in one-on-one meetings with investors through organized conference calls. A live webcast of the event will be available on OPKO's investor website, along with a replay accessible for a limited time.
OPKO is focused on establishing leading positions in rapidly growing markets by leveraging its pharmaceutical and diagnostics expertise.